Best Biologic for Crohn's Disease in 2026
Comparing FDA-approved biologics for Crohn's by efficacy, mechanism, and patient factors
Key Takeaways
- Multiple biologics are FDA-approved for Crohn's — choice depends on disease location, severity, and prior treatment
- Skyrizi showed superiority over Stelara in the SEQUENCE head-to-head trial for Crohn's
- Entyvio's gut-selective mechanism is attractive for patients with infection concerns
- TNF inhibitors (Humira, Remicade) have the longest track record and extensive real-world data
- Most insured patients pay $0–$35/month through manufacturer savings programs
FDA-Approved Biologics for Crohn's Disease
| Medication | Class | Route | Key Advantage |
|---|---|---|---|
| Skyrizi | IL-23 | IV then SQ | Superior to Stelara in head-to-head trial (SEQUENCE) |
| Stelara | IL-12/23 | IV then SQ | Strong safety profile; every 8 weeks maintenance |
| Humira | TNF-α | Subcutaneous | Longest track record; biosimilars available |
| Remicade | TNF-α | IV infusion | Fast onset; often combined with immunomodulator |
| Entyvio | Anti-integrin | IV or SQ | Gut-selective; minimal systemic immunosuppression |
| Rinvoq | JAK1 | Oral daily | Oral option; fast onset; black box warnings apply |
| Omvoh | IL-23 | IV then SQ | Newest IL-23 inhibitor; strong Crohn's trial data |
| Cimzia | TNF-α | Subcutaneous | Minimal placental transfer — preferred in pregnancy |
How Gastroenterologists Choose a Crohn's Biologic
Biologic-naive patient
TNF inhibitors (Humira, Remicade) or IL-23 inhibitors (Skyrizi, Stelara) are commonly used first-line. IL-23 inhibitors are increasingly preferred for their safety profile.
Failed a TNF inhibitor
Switching mechanism class is recommended. IL-23 inhibitors (Skyrizi, Stelara) or Entyvio are strong options after TNF failure.
Infection concerns or older patients
Entyvio's gut-selective mechanism provides effective Crohn's treatment with minimal systemic immunosuppression — a significant advantage for high-risk patients.
Prefers oral therapy
Rinvoq (upadacitinib) is the only oral biologic approved for Crohn's disease. Discuss the JAK inhibitor black box warnings with your gastroenterologist.
💊 BiologicHealthPlus Carries All Crohn's Biologics
Prior authorization, copay enrollment, and free cold-chain delivery for Skyrizi, Stelara, Humira, Remicade, Entyvio, Rinvoq, Omvoh, and Cimzia.
Crohn's Disease Guide →📚 Sources & Further Reading
Content developed with reference to leading health organizations, peer-reviewed research, and FDA prescribing information.
Medical Disclaimer: Educational content reviewed by the BiologicHealthPlus Clinical Team. Consult your healthcare provider for personalized advice. Last reviewed: August 2026.